港股通创新药ETF嘉实（520970）跟踪中证港股通创新药指数，前十大权重股分别为药明生物、百济神 州、信达生物、康方生物、中国生物制药、石药集团、翰森制药、药明康德、三生制药、晶泰控股，权 重合计超71.71%。 港股通创新药ETF嘉实（520970）管理费+托管费为0.60%/年，既适合普通投资者作为长期配置工具， 也能满足专业投资者的灵活交易需求。 风险提示：基金有风险，投资需谨慎。 资讯所属栏目还有更多独家策划、专家专栏，免费查阅>> 1月7日消息，据同花顺数据显示，截至09:40，港股通创新药指数上涨1.59%，个股方面，康方生物涨超 3%，科伦博泰生物-B、石药集团、翰森制药等涨超2%，中国生物制药、信达生物、药明生物、百济神 州、药明康德等涨超1%，三生制药跟涨。 热门ETF方面，港股通创新药ETF嘉实（520970）涨1.93%，盘中成交额达994.06万元，换手率达 0.91%。 东海证券认为，2026年我国医药生物行业将正式步入创新药大时代，创新药将逐渐占据我国医药生物行 业的主导地位，医保商保的互补结合将长期打开支付空间的天花板，创新药将持续蓬勃发展。国内方 面，2026年将更多关注创新 ...

Core Viewpoint - The innovation drug sector in China is experiencing significant growth due to favorable policy developments, with the introduction of new drug listings in the national medical insurance catalog and commercial insurance, providing a stable policy outlook for innovative drug companies [1][2]. Group 1: Industry Trends - The China Hong Kong Stock Connect Innovation Drug Index increased by 0.30% as of December 11, 2025, with notable gains from companies such as Zhaoyan New Drug (+4.15%) and Rongchang Bio (+2.85%) [1]. - The national medical insurance catalog for 2025 successfully added 114 new drugs, including 50 innovative drugs, achieving a historical high success rate of 88% [1]. - The introduction of dual catalogs for medical insurance and commercial insurance is expected to directly benefit innovative drug companies, indicating a positive industry outlook [1]. Group 2: Market Opportunities - The top ten weighted stocks in the China Hong Kong Stock Connect Innovation Drug Index account for 72.68% of the index, highlighting the concentration of investment in leading innovative drug companies [2]. - The Harvest Innovation Drug ETF (520970) closely tracks the index, providing investors with access to leading companies involved in drug research, development, and production [2]. - Investors without stock accounts can leverage the Hong Kong Stock Connect Innovation Drug ETF linked fund (024700) to capitalize on the growth opportunities in the innovative drug sector [2].

Core Viewpoint - The Hong Kong stock market experienced a pullback after reaching new highs, with the Hang Seng Index and Hang Seng Tech Index both declining. Despite this, there are still optimistic projections for future growth, particularly in the technology sector, which is expected to attract investor interest [1][2]. Market Performance - As of October 8, the Hang Seng Index fell by 0.48% to 26,829.46 points, while the Hang Seng Tech Index decreased by 0.55% to 6,514.19 points. The indices had previously reached new highs on October 2, with the Hang Seng Index peaking at 27,381.84 points [1][2]. - Year-to-date, the Hang Seng Index and Hang Seng Tech Index have increased by 33.75% and 45.79%, respectively [2]. Fund Performance - Several Hong Kong-themed funds have shown outstanding performance, with some achieving returns as high as 155% in the first three quarters of the year. Notable funds include the Huatai-PineBridge Hong Kong Advantage Selected Mixed Fund and the Bank of China Hong Kong Stock Connect Pharmaceutical Mixed Fund, which reported returns of 155.14% and 126.55%, respectively [3][2]. Sector Focus - The innovative pharmaceutical sector has gained significant attention, with the China Securities Index tracking the Hong Kong Stock Connect Innovative Pharmaceutical Index showing a year-to-date increase of 118.52% [3]. - The long-term outlook for the Hong Kong market remains positive, particularly in core areas such as the internet, innovative pharmaceuticals, and medical biotechnology, which are expected to attract capital inflows [3][4]. Investment Strategy - Future investment opportunities in Hong Kong-themed funds are anticipated, especially those focusing on new economy, technology, and innovation sectors. Investors are advised to prioritize reasonably valued assets with clear growth potential and consider a systematic investment approach [4].

Core Viewpoint - The stock of Yaojie Ankang experienced extreme volatility on September 16, with a peak increase of 63% followed by a dramatic drop of 53.7%, resulting in a market value loss exceeding 190 billion HKD [2][5]. Company Overview - Yaojie Ankang, established in 2014, focuses on developing innovative small molecule therapies for cancer, inflammation, and cardiovascular metabolic diseases. The company currently has no commercialized products and reported losses of 343 million HKD and 275 million HKD for 2023 and 2024, respectively [5][6]. Stock Performance - The stock was listed on June 23, 2023, at an initial price of 13.15 HKD, and saw its value soar over 50 times, reaching a market capitalization close to 270 billion HKD, making it one of the top biotech firms in the Hong Kong market [3][5]. - On September 16, the stock price peaked at 679.5 HKD before closing at 192 HKD, marking a 72% decline from its intraday high [5][6]. ETF and Market Impact - Several ETFs tracking the National Index for Hong Kong Stock Connect Innovation were implicated in high-level buying during the stock's surge, raising concerns about their role as "bag holders" after the price drop [6][9]. - The National Index for Hong Kong Stock Connect Innovation saw a decline of 3.86% on the same day, with corresponding ETFs experiencing significant losses, indicating a direct impact from Yaojie Ankang's stock volatility [7][8]. Market Dynamics - The stock's rapid rise was attributed to limited liquidity, with only 549,000 shares available for trading, which allowed small amounts of capital to cause significant price fluctuations [6]. - The lack of transparency regarding the inclusion of Yaojie Ankang in the ETF indices has raised concerns among investors, potentially affecting their confidence and leading to unanticipated losses [9].

Core Viewpoint - Multiple Hong Kong innovative drug companies' stock prices surged today, driven by related concept stocks, with the Hong Kong Innovative Drug ETF showing strong performance, including a half-day trading volume of 2.29 billion yuan for the Hong Kong Innovative Drug ETF (159570) [1][6]. Group 1: ETF Performance - The Hong Kong Innovative Drug ETF (520880) increased by 3.76%, with a trading volume of 2.04 billion yuan and a total size of 283 million units [3][6]. - Other related ETFs also saw significant gains, with the Hong Kong Innovative Drug ETF (159570) rising by 3.54% and achieving a trading volume of 2.29 billion yuan, while its total size reached 5.513 billion units [6][10]. - The performance of various ETFs in the innovative drug sector includes: - Hong Kong Innovative Drug ETF (520880): 3.76% increase, 283 million units - Hang Seng Innovative Drug ETF (520500): 3.74% increase, 466 million units - Hong Kong Innovative Drug ETF (159567): 3.57% increase, 2.031 billion units - Hong Kong Innovative Drug ETF (159570): 3.54% increase, 5.513 billion units [2][6]. Group 2: Investment Logic - The investment logic indicates that policy support for innovative drugs is improving, with an expected increase in the number and innovation of new drug launches. The structure of medical insurance fund expenditures is shifting towards innovative drugs, leading to a more reasonable pricing mechanism [3][7]. - The supply side is focusing on high-quality innovations and strengthening support for innovative drugs going abroad. The pharmaceutical industry has undergone valuation digestion, placing innovative drug valuations at a low point, which provides a basis for systematic rebound [3][7]. Group 3: Index Characteristics - The Guozheng Hong Kong Innovative Drug Index selects companies involved in innovative drug research and production, reflecting the operational characteristics of listed companies in the innovative drug industry. The index covers the innovative drug sector comprehensively, with a high proportion of other biological products and chemical preparations [7][10]. - The index is characterized by a market capitalization distribution skewed towards small and mid-cap stocks, with valuations at historical lows, indicating high investment cost-effectiveness [7][10].

6月4日，港股午间收盘，恒生指数涨0.72%，恒生科技指数涨1.01%，中证港股通创新药指数 (931250.CSI)上涨3.79%，信达生物上涨15.07%，再鼎医药涨10.97%，泰格医药涨超9%。 相关ETF方面，港股创新药50ETF（513780）早盘涨4%，盘中最高价达1.391元创历史新高，成交额为 2.99亿元，暂居同标的产品第一。资金流向方面，截至6月3日，该ETF已连续3个交易日获资金净流 入，累计净流入额为6333.69万元。该ETF最新流通份额为4.19亿份，最新流通规模为5.53亿元。值得一 提的是，截至6月4日午间收盘，港股创新药50ETF（513780）年内涨超45%。 港股创新药50ETF(513780.SH)紧密跟踪中证港股通创新药指数(931250.CSI)，中证港股通创新药指数从 港股通范围内选取50只业务涉及创新药研发以及为制药企业提供药物研究、开发和生产等服务的上市公 司证券作为指数样本，以反映港股通范围内创新药上市公司证券的整体表现。该ETF配备了2只场外联 接基金（A：023597/C：023598）。 全球来看，BD交易早已存在，买方通常是手握充沛现金流的知名大药 ...